Masaki Kumondai

Dr. Masaki Kumondai

Tohoku University
orcid

Research Focus & Metrics

Academic Career Length

10Years (2017-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
1 December 2018 in Drug Metabolism and Pharmacokinetics
Verified
Journal Article
Closed access
TSTakahiro Saito
Takahiro Saito
EREvelyn Marie Gutiérrez Rico
Evelyn Marie Gutiérrez Rico
AKAoi Kikuchi
Aoi Kikuchi
AKAkira Kaneko
Akira Kaneko
MKMasaki Kumondai
Masaki Kumondai
Masahiro HiratsukaMasahiro Hiratsuka
Masahiro Hiratsuka

1 March 2017 in Drug Metabolism and Disposition
Verified
Journal Article
Open access
HHHiroki Hosono
Hiroki Hosono
MKMasaki Kumondai
Masaki Kumondai
MMMasamitsu Maekawa
Masamitsu Maekawa
HYHiroaki Yamaguchi
Hiroaki Yamaguchi
NMNariyasu Mano
Nariyasu Mano
Masahiro HiratsukaMasahiro Hiratsuka
Masahiro Hiratsuka
CYP2A6, a member of the cytochrome P450 (P450) family, is one of the enzymes responsible for the metabolism of therapeutic drugs and such tobacco components as nicotine, 4-(methylnitrosamino)-1-(3-pyridyl)-1-butanone, and N-nitrosodiethylamine. Genetic polymorphisms in CYP2A6 are associated with individual variation in smoking behavior, drug toxicities, and the risk of developing several cancers. In this study, we conducted an in vitro analysis of 34 allelic variants of CYP2A6 using nicotine and coumarin as representative CYP2A6 substrates. These variant CYP2A6 proteins were heterologously expressed in 293FT cells, and their enzymatic activities were assessed on the basis of nicotine C-oxidation and coumarin 7-hydroxylation activities. Among the 34 CYP2A6 variants, CYP2A6.2, CYP2A6.5, CYP2A6.6, CYP2A6.10, CYP2A6.26, CYP2A6.36, and CYP2A6.37 exhibited no enzymatic activity, whereas 14 other variants exhibited markedly reduced activity toward both nicotine and coumarin. These comprehensive in vitro findings may provide useful insight into individual differences in smoking behavior, drug efficacy, and cancer susceptibility.

Verified
Journal Article
Open access
PDF file
AAAi Abe
Ai Abe
MMMasamitsu Maekawa
Masamitsu Maekawa
TSToshihiro Sato
Toshihiro Sato
YSYu Sato
Yu Sato
MKMasaki Kumondai
Masaki Kumondai
NMNariyasu Mano
Nariyasu Mano
Niemann–Pick disease type C (NPC) is an autosomal recessive disease caused by a functional deficiency of cholesterol-transporting proteins in lysosomes, and exhibits various clinical symptoms. Since mitochondrial dysfunction in NPC has recently been reported, cholesterol catabolism to steroid hormones may consequently be impaired. In this study, we developed a comprehensive steroid hormone analysis method using liquid chromatography/tandem mass spectrometry (LC–MS/MS) and applied it to analyze changes in steroid hormone concentrations in NPC model cells. We investigated the analytical conditions for simultaneous LC–MS/MS analysis, which could be readily separated from each other and showed good reproducibility. The NPC phenotype was verified as an NPC model with mitochondrial abnormalities using filipin staining and organelle morphology observations. Steroid hormones in the cell suspension and cell culture medium were also analyzed. Steroid hormone analysis indicated that the levels of six steroid hormones were significantly decreased in the NPC model cell and culture medium compared to those in the wild-type cell and culture medium. These results indicate that some steroid hormones change during NPC pathophysiology and this change is accompanied by mitochondrial abnormalities.

1 July 2024 in YAKUGAKU ZASSHI
Verified
Journal Article
Closed access
PDF file
AOAyaka Otsuki
Ayaka Otsuki
MKMasaki Kumondai
Masaki Kumondai
DKDaisuke Kobayashi
Daisuke Kobayashi
MKMasafumi Kikuchi
Masafumi Kikuchi
YUYugo Ueki
Yugo Ueki
NMNariyasu Mano
Nariyasu Mano
Venetoclax (VEN) is used in patients with acute myeloid leukemia (AML) and is primarily metabolized by CYP3A4, a major drug-metabolizing enzyme. Patients with AML simultaneously administered VEN and CYP3A4 inhibitors require a more appropriate management of drug–drug interactions (DDIs). Here, we report two cases of patients with AML (54-year-old man and 22-year-old woman) administrated VEN and CYP3A4 inhibitors, such as posaconazole, cyclosporine, or danazol. In the first case, we evaluated the appropriateness of timing for adjusting VEN dosage subsequent to the cessation of posaconazole. Consequently, modifying the VEN dosage in conjunction with the cessation of Posaconazole simultaneously may result in elevated plasma VEN levels. In the second case, plasma VEN concentrations were markedly elevated when co-administered with several CYP3A4 inhibitors. Additionally, in vitro assays were conducted for reverse translational studies to analyze CYP3A4 inhibition. CYP3A4 inhibition by combinatorial administration of cyclosporine A and danazol was demonstrated in vitro, which potentially explains the increasing plasma VEN concentrations observed in clinical settings. Although the acquisition of therapeutic effects is a major priority for patients, frequent therapeutic drug monitoring and dosage adjustments considering DDIs would be important factors in chemotherapy.

1 December 2018 in Drug Metabolism and Pharmacokinetics
Verified
Journal Article
Closed access
MKMasaki Kumondai
Masaki Kumondai
AIAkio Ito
Akio Ito
EHEiji Hishinuma
Eiji Hishinuma
AKAoi Kikuchi
Aoi Kikuchi
TSTakahiro Saito
Takahiro Saito
Masahiro HiratsukaMasahiro Hiratsuka
Masahiro Hiratsuka

Verified
Journal Article
Open access
PDF file
慶三慶太郎 三好
慶太郎 三好
EHEiji Hishinuma
Eiji Hishinuma
NMNaomi Matsukawa
Naomi Matsukawa
YSYoshitaka Shirasago
Yoshitaka Shirasago
MWMasahiro Watanabe
Masahiro Watanabe
NMNariyasu Mano
Nariyasu Mano
Niemann–Pick disease type C (NPC) is an autosomal recessive disorder with progressive neurodegeneration. Although the causative genes were previously identified, NPC has unclear pathophysiological aspects, and patients with NPC present various symptoms and onset ages. However, various novel biomarkers and metabolic alterations have been investigated; at present, few comprehensive proteomic alterations have been reported in relation to NPC. In this study, we aimed to elucidate proteomic alterations in NPC and perform a global proteomics analysis for NPC model cells. First, we developed two NPC cell models by knocking out NPC1 using CRISPR/Cas9 (KO1 and KO2). Second, we performed a label-free (LF) global proteomics analysis. Using the LF approach, more than 300 proteins, defined as differentially expressed proteins (DEPs), changed in the KO1 and/or KO2 cells, while the two models shared 35 DEPs. As a bioinformatics analysis, the construction of a protein–protein interaction (PPI) network and an enrichment analysis showed that common characteristic pathways such as ferroptosis and mitophagy were identified in the two model cells. There are few reports of the involvement of NPC in ferroptosis, and this study presents ferroptosis as an altered pathway in NPC. On the other hand, many other pathways and DEPs were previously suggested to be associated with NPC, supporting the link between the proteome analyzed here and NPC. Therapeutic research based on these results is expected in the future.